Adialante aims to revolutionize the MRI industry with innovative, clinically effective imaging systems that make advanced imaging more accessible and efficient than ever before. The company’s flagship product is a groundbreaking MRI scanner that is compact (< 100 sq ft), affordable, and silent. Despite its small size and low cost, it produces significantly higher quality images than competing products.

Auricle is developing a minimally-invasive cochlear neurostimulation device technology to restore hearing in adults with severe high-frequency hearing loss. The condition, which makes it increasingly difficult to understand speech, affects over one million adults in the US. The condition has few treatment options; hearing aides can become less effective over time, and the only other solution is cochlear implants, an expensive and irreversible treatment that can risk residual hearing.

AVaTar is taking aim at valvular heart disease by combining a novel surgical method and a set of innovative medical devices to enable aortic or pulmonary valve reconstruction using autologous tissue. The approach seeks to address limitations in valve reconstruction options for children. Currently, procedures for pediatric patients are complicated by a lack of appropriately sized valves and children’s natural, rapid growth. AVaTAR’s approach also has applications for adults.

Biobot Surgical develops robotic-assisted systems for prostate cancer diagnosis and treatment. The company is at the center of the global shift in prostate cancer care from transrectal biopsy toward transperineal approaches, driven by the need to reduce infection risk, improve access to difficult-to-reach lesions, and support more precise, image-guided procedures. Biobot’s Mona Lisa system, a robotic transperineal platform for targeted prostate biopsy and focal ablation procedures, integrates robotic needle guidance, MRI-ultrasound image fusion, workflow standardization and procedure data capture. The company has deployed more than 80 systems globally and is currently planning its U.S. market strategy..

Autoimmune diseases are the third most common category of disease in the United States, affecting up to 27 million people. Boomerang Medical is a bioelectronic medicine company developing technology to advance the treatment of autoimmune diseases by harnessing the body’s own “peripheral wiring” in order to manage inflammation and immune response.  Boomerang Medical is backed by Arboretum Ventures, a venture capital firm specializing in companies that improve patient outcomes and reduce healthcare system costs.

Cinch Innovations is developing a novel implant for the treatment of proximal biceps tendon issues, a common source of shoulder pain. Severing the tendon (tenotomy) relieves pain but can result in cosmetic deformity and functional loss. Biceps tenodesis—anchoring the tendon to bone or soft tissue—is preferred, but current arthroscopic techniques can be technically demanding and time-consuming.

Corveus Medical is developing a catheter-based procedure to reduce the clinical burden of congestive heart failure for patients who continue to suffer debilitating symptoms with inadequate treatment options. Corveus’ technology targets a newly identified driver behind this disease.

Vertigo affects roughly 8% of US adults every year. It can be disabling and is often mismanaged because it is hard to identify the cause. It is also costly, resulting in $60B in annual US medical expenditures. DizzyEX is developing a wearable patch designed to capture clinically recognized markers during dizzy episodes with the goal of diagnosing the underlying causes of vertigo.

Current chronic therapies for short bowel syndrome (SBS), a malabsorption disorder caused by the lack of a functional small intestine, include expensive medication and intestinal surgery. These approaches have low success rates and a staggering average 5-year cost of care of $1.6 million per patient. Eclipse Regenesis is developing the first restorative therapy for pediatric and adult SBS patients with the Eclipse XL1 Distraction Enterogenesis System, which harnesses the body’s own tissue regenerative capabilities to produce new, fully functional intestine.

Skin cancer is the most common form of malignancy, with more individuals diagnosed each year than for all other cancers combined. For the last 150 years, these malignancies have required an invasive biopsy for diagnosis, but Enspectra is leading a digital transformation in pathology by imaging real-time cellular anatomy in living tissue, without cuts or stains.

Up to 60 million individuals in the U.S. suffer from debilitating gastrointestinal disorders. G-Tech Medical is developing a wearable technology aimed at improving outcomes and reducing costs by non-invasively monitoring gastrointestinal tract activity.

One hundred seventy-eight million adults in the United States are missing at least one tooth, and a surprising 40 million are missing all their teeth. Dental implants are the top treatment choice of treatment, but this solution is utilized by less than  2 percent of those impacted by tooth loss because of limited accessibility, high cost, high risk and long treatment time. iDentical is leveraging the latest 3D technology to offer a safer, faster and more affordable solution through its drill-free, non-invasive dental implants.

Immergo is developing a virtual reality platform for physical therapists that aims to improve the accessibility, experience, and accuracy of remote physical therapy care. The company offers AI-enabled patient documentation, and immersive remote care with accurate metrics for real-time interaction with patients in 3D worlds.

LearUp is an AI-powered, fully integrated cloud-based platform designed to revolutionize clinical trial management by enhancing operational efficiency, accelerating trial execution, and ensuring data integrity. A real-time smart platform, LearUp actively connects data silos, automates routine processes, and provides actionable insights to keep trials on track

Maguro Surgical was founded by urologists and scientists to tackle the shortcomings of existing kidney stone removal tools. Its groundbreaking technology––the MagStone System––deploys a magnetic coating to facilitate clearance of kidney stone fragments of any size accommodated by the ureter. By ensuring more complete stone removal, MagStone aims to improve overall procedure efficiency and significantly reduce the need for repeat surgeries. Recognizing MagStone’s revolutionary potential, the FDA awarded it Breakthrough Device Designation. Currently, Maguro is completing preclinical testing for the MagStone system.

Approximately 50 percent of all women in the U.S. will suffer symptoms of a pelvic floor disorder resulting from childbirth by the time they turn 55, and over 20 million suffer from pelvic pain. Materna has developed an obstetrics and gynecology platform of medical devices: the first, Prep, is aimed at preventing maternal pelvic injuries during childbirth and shortening delivery time; the second, Milli, is helping treat pelvic pain and dyspareunia.

Preterm births and subsequent complications are the leading cause of death for infants under the age of one, with at least one million cases worldwide. Two-thirds of preterm births are caused by short cervix and early rupture of the amniotic sac . Current treatment options are limited and often ineffective. Novocuff is developing a unique device to reinforce the cervix and improve amniotic fluid retention, which would improve outcomes for mothers and babies

As the third-leading cause of death worldwide, chronic obstructive pulmonary disease (COPD) is a group of diseases that causes airway blockage and breathing problems. Ryme is focused on alleviating the suffering of patients who struggle to breathe by targeting the autonomous nervous system.  The condition impacts more than 375 million people worldwide at an annual cost of approximately $50 billion and is a huge burden to healthcare systems around the world.

54 million Americans suffer from obstructive sleep apnea (OSA) which is associated with serious adverse health outcomes including an elevated risk of heart attack, stroke and diabetes. As many as half of sufferers fail first line therapy (CPAP). Somnair is working to improve the lives of OSA sufferers by developing a noninvasive neurostimulation device that opens the airway using a proprietary therapy delivery system.

Synkopi Inc. is developing a battery powered bi-atrial pressure monitoring device (PatHFinder) to improve medical management of HF and treduce hospitalization and mortality.  PatHFinder combines a custom-built pressure sensor with a wireless communication system to safely and reliably measure vital parameters and transmit themto a base station. The company has demonstrated feasibility of the device in pre-clinical trials and aims to initiate early feasibility studies in humans by late 2026.

Tidal Medical is focused on improving adherence to respiratory therapy in post-surgical patients. After surgery, many patients are asked to use incentive spirometer, a hand-held device that exercises the lungs, multiple times per hour to improve breathing and prevent lung infections. However, adherence is generally poor. Tidal Medical is working to remedy this with a smart device that reminds patients and tracks performance and outcomes data.